NCT03528187

Brief Summary

Obesity and its related conditions account for up to 5%of all health care spending in the UK and this is expected to double by 2030. Following weight loss, significant improvement in these obesity-related illnesses has been reported. However, there is limited understanding of how these improvements happen and in particular, little dedicated work has been done using imaging in the obese population to look at the effects of treatment. Magnetic resonance imaging (MRI) is an imaging technique that allows assessment of fat concentration and volume without the use of ionising radiation. It is safe, non-invasive and well-tolerated by most patients. There are several MRI imaging techniques that be can used for fat quantification. These include MR spectroscopy and Dixon methods with measurement of fat fraction. These techniques measure the fat in the body organs and also the fat in the abdomen and skin. Recent technical developments mean that the whole body can be scanned relatively quickly (typically 30-40 minutes).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 27, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

May 17, 2018

Completed
14 days until next milestone

Study Start

First participant enrolled

May 31, 2018

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 6, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 6, 2021

Completed
Last Updated

October 25, 2023

Status Verified

October 1, 2023

Enrollment Period

3.5 years

First QC Date

April 27, 2018

Last Update Submit

October 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The effects of obesity treatments on individual organ using MRI

    Measures are fat fraction in individual organs before and after therapeutic interventions

    15 years

Secondary Outcomes (1)

  • Imaging measure of individual organ with metabolic markers of disease collected as part of usual care or parallel research studies.

    15 years

Study Arms (3)

Patient Cohort 1

* Age 18 or over * BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin) * Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications \[dietary change, behavioural therapy, increased physical activity\], surgical intervention or pharmacological treatment) as part of their usual clinical care * Informed written consent * Able to tolerate MRI

Other: MRIOther: Written Consent

Patient Cohort 2

* Age 18 or over * Attending weight management service at UCLH * Informed written consent * Able to tolerate MRI

Other: MRIOther: Written Consent

Controls

* Age 18 or over * BMI less than 25 * Informed written consent * Able to tolerate MRI

Other: MRIOther: Written Consent

Interventions

MRIOTHER

MRI scan (not involving ionising radiation) The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

ControlsPatient Cohort 1Patient Cohort 2

Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

ControlsPatient Cohort 1Patient Cohort 2

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be recruited by suitably trained members of the research team on the study delegation log including research fellows, nurses, surgeons and endocrinologists working in a tertiary bariatric referral centre at UCLH on a person-to-person basis.

You may qualify if:

  • Age 18 or over
  • BMI greater than or equal to 30
  • Due to undergo or referred for a formal treatment intervention for obesity, as part of their usual clinical care.
  • Informed consent
  • Cohort 2
  • Age 18 or over
  • Attending the weight management service at UCLH
  • Informed consent
  • Controls
  • Age 18 or over
  • BMI less than 25
  • Informed consent

You may not qualify if:

  • Absolute contraindication to MRI scan (e.g. metal foreign object)
  • Unable to tolerate MRI scan (e.g. due to claustrophobia)
  • MRI bore size inadequate to accommodate the patient
  • Previous weight loss surgery (e.g. gastric band, gastric bypass, sleeve gastrectomy) \[Cohort 1 only\]
  • Unable to give consent
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University College London Hospital

London, United Kingdom

Location

Related Publications (4)

  • Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging. 2011 Oct;34(4):729-749. doi: 10.1002/jmri.22775. Epub 2011 Sep 16.

    PMID: 22025886BACKGROUND
  • Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254.

    PMID: 17715408BACKGROUND
  • Hernando D, Sharma SD, Aliyari Ghasabeh M, Alvis BD, Arora SS, Hamilton G, Pan L, Shaffer JM, Sofue K, Szeverenyi NM, Welch EB, Yuan Q, Bashir MR, Kamel IR, Rice MJ, Sirlin CB, Yokoo T, Reeder SB. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med. 2017 Apr;77(4):1516-1524. doi: 10.1002/mrm.26228. Epub 2016 Apr 15.

    PMID: 27080068BACKGROUND
  • Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004 Jul-Aug;22(4):275-82.

    PMID: 15468951BACKGROUND

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2018

First Posted

May 17, 2018

Study Start

May 31, 2018

Primary Completion

December 6, 2021

Study Completion

December 6, 2021

Last Updated

October 25, 2023

Record last verified: 2023-10

Locations